DCs can increase tumor metastasis levels by enhancing Treg responses and inhibiting the cytotoxicity of CD8+ T cells, consistent with high levels of Treg markers FOXP3, CCR8, STAT5B, and TGFβ (75). Here, CD8A is linked to neoplasm.